Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
22 active Medicare policies list M02.39, and 2 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
J5 · Effective Sep 16, 2017
J8 · Effective Sep 16, 2017
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
2 policies from 1 payer
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M02.39 |
|---|---|---|
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) | Feb 20, 2024 | Covered |
| Polymerase Chain Reaction Testing: Selected Indications | Feb 9, 2024 | Covered |
JF · Effective Oct 1, 2015
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2026
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
J5 · Effective Nov 27, 2025
National · Effective Oct 1, 2026
National · Effective Jan 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026